Product logins

Find logins to all Clarivate products below.


John Lebbos

Partner, Commercial Strategy Consulting

John Lebbos, MD is a Partner in Clarivate’s Commercial Strategy Consulting team.​​​

He is currently a practice leader in Product and Market Opportunity Assessments & Strategy and has over 20 years of experience supporting clients with product and therapeutic area strategy, functional patient journey analysis, opportunity and market assessments, disease area analysis, sales forecasting, and portfolio planning/strategy.​​

Formerly a Vice President in DRG’s infectious disease syndicated research group, Dr. Lebbos led the Infectious Disease research team and has had over 20 years of experience conducting market analysis, opportunity assessments and prioritization and product strategy. ​​

Dr. Lebbos received his medical degree from the University of Massachusetts. Prior to pursuing his medical degree, he attended Tufts University where he graduated summa cum laude in chemical engineering.


arrow_forward
Get in touch with John

Latest news

News June 17, 2026
Clarivate Releases Journal Citation Reports 2026

Advancing transparency and responsible journal evaluation London, U.K. June 17 2026 — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the release of the Journal…

Partner news June 16, 2026
U.S. News Unveils 2026-2027 Best Global Universities Rankings

Universities in more than 100 countries are evaluated in the newest edition. Washington, D.C. – June 16, 2026 – U.S. News & World Report, the global authority in education rankings…

Partner news
News June 15, 2026
Clarivate’s IPfolio Selected by Mitsubishi Fuso

Managing intellectual property more efficiently with leading data and expertise London, U.K. June 15, 2026. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Mitsubishi…

Related resources

Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization